Physician profile
Mark Alan Earhart
NPI 1073536439
$13,018.81
in general payments reported to CMS, 2019-2025
53 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,993 · 2020: $2,291 · 2021: $1,508 · 2022: $2,274 · 2023: $2,209 · 2024: $1,461 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,910 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,909.90 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,099.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,003.61 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $984.07 | 2021-2025 | |
| Abbvie INC. | $820.18 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $800.90 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Pfizer INC. | $722.85 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $622.29 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $612.24 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Amarin Pharma, INC. | $374.36 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $348.37 | 2019-2023 | Livalo, Seglentis |
| Amgen INC. | $294.08 | 2019-2025 | Evenity, Prolia, Prolia |
| Glaxosmithkline, LLC. | $221.71 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $214.65 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $212.79 | 2019-2020 | |
| Harmony Biosciences LLC | $195.88 | 2022-2025 | Wakix |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $183.09 | 2021-2025 | Rexulti |
| Abbott Laboratories | $169.79 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $149.92 | 2021-2023 | Qelbree |
| Noven Therapeutics, LLC | $142.52 | 2023-2025 | Xelstrym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.44 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $128.12 | 2022-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $106.03 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $101.89 | 2022-2024 | Quviviq |
| Genentech USA, INC. | $95.25 | 2019-2021 | |
| Corium, LLC | $93.41 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $93.06 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $91.80 | 2019-2022 | |
| Baxter Healthcare | $80.50 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Astellas Pharma US INC | $67.09 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.98 | 2024-2025 | Caplyta |
| Aytu Biopharma, INC. | $57.29 | 2019 | |
| Shire North American Group INC | $57.15 | 2019 | |
| Medtronic, INC. | $55.79 | 2021-2025 | Minimed 780g |
| Tris Pharma INC | $51.75 | 2023-2025 | Dyanavel Xr |
| Novartis Pharmaceuticals Corporation | $44.83 | 2022-2023 | |
| Corcept Therapeutics | $43.13 | 2023 | Korlym |
| Axsome Therapeutics, INC. | $42.40 | 2022-2023 | Sunosi |
| Adlon Therapeutics L.P. | $40.88 | 2019-2021 | |
| Horizon Therapeutics Plc | $40.20 | 2020 | |
| Exact Sciences Corporation | $39.68 | 2024 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $37.82 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.79 | 2022 | |
| Sanofi Pasteur INC. | $31.31 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $30.70 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.47 | 2022-2023 | Eliquis |
| Endo Pharmaceuticals INC. | $27.29 | 2019 | |
| Dexcom, INC. | $24.24 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $21.03 | 2025 | |
| Kaleo, INC. | $20.77 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.81 | 2019 | |
| Vivus LLC | $12.03 | 2019 | |
| Gilead Sciences, INC. | $11.94 | 2019 | |
| Medtronic Vascular, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Earhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.